drugset
drugset / Trial / NCT04225039

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

NCT04225039 ↗

Phase 2 Active not recruiting 39 enrolled University of Pennsylvania Incyte Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.

Timeline

Start
2020-06-23
Primary completion
2022-09-08
Completion
2029-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject RAGIFILIMAB Monoclonal antibody 300 mg —
Subject Retifanlimab Monoclonal antibody 500 mg —

Indications

glioblastoma